AzTrials
AzTrials

TherapyPhase 2/3NCT02455609

Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain

A Phase 2/3 study testing intrathecal drug administration, Dexmedetomidine and ketamine in people with Therapy and Pain Management, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Currently, opioids are widely used for pain relief, but they often provide sub-optimal analgesia with occasional serious side effects. Preservative-free ketamine hydrochloride was introduced as a spinal anesthetic more than twenty years ago and found to have advantages over local anesthetics. Read more about this study

Who is it for?
Ages 30 to 50 years
Conditions the study is for
Therapy, Pain Management
What is being tested?
intrathecal drug administration, Dexmedetomidine and ketamine
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
No sites listed yet
Study dates
Mar 2015to Sep 2015
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Aged 30-50 years
  • American Society of Anesthesia (ASA) I-II patients
  • scheduled for major abdominal cancer surgery

Who cannot join

  • known allergy to the study drugs.
  • significant cardiac, respiratory, renal or hepatic disease
  • coagulation disorder
  • infection at the site of intrathecal injection
  • drug or alcohol abuse
  • BMI > 30 kg/m2
  • psychiatric illnesses that would interfere with perception and assessment of pain

About this study

Official title: Intrathecally Administered Ketamine, Dexmedetomidine, and Their Combination With Bupivacaine for Postoperative Analgesia in Major Abdominal Cancer Surgery

Currently, opioids are widely used for pain relief, but they often provide sub-optimal analgesia with occasional serious side effects. Preservative-free ketamine hydrochloride was introduced as a spinal anesthetic more than twenty years ago and found to have advantages over local anesthetics. Intrathecal dexmedetomidine provides an analgesic effect in postoperative pain without severe sedation. The objectives of this study were to compare the efficacy and safety of intrathecally administered dexmedetomidine, ketamine, or their combination when added to bupivacaine for postoperative analgesia in major abdominal cancer surgery.

Read the detailed description

This study was approved by the ethics committee of South Egypt Cancer Institute, Assiut University, Assiut, Egypt. After obtaining a written informed consent, 90 American Society of Anesthesia (ASA) I-II patients aged 30-50 years and scheduled for major abdominal cancer surgery were included in the study. Patients with a known allergy to the study drugs, significant cardiac, respiratory, renal or hepatic disease, coagulation disorder, infection at the site of intrathecal injection, drug or alcohol abuse, BMI > 30 kg/m2 , and psychiatric illnesses that would interfere with perception and assessment of pain were excluded from the study.

Preoperatively, patients were taught how to evaluate their own pain intensity using the visual analogue scale (VAS), scored from 0 -10 (where 0 = no pain, and 10 = the worst pain imaginable).

Oral diazepam (5 mg) was taken the night before surgery. Up on arrival at the operative theatre, a 16-gauge catheter was introduced intravenously at the dorsum of the hand; lactated Ringer's solution 10 mg/kg was infused intravenously over 10 min. before initiation of spinal anesthesia. Basic monitoring probes (electrocardiography, non invasive blood pressure, O2 saturation, and temperature) were applied. Patients were placed in the setting position and a 25-gauge Quincke needle was placed in the L2-3 or L3-4 interspaces.

Patients were randomly divided, by selecting sealed envelopes into one of three groups 30 patients each:

  • The dexmedetomidine group (group I) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume intrathecally.
  • The ketamine group (group II) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
  • Dexmedetomidine + Ketamine group (group III) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.

Immediately after their intrathecal injection, the patients were placed in the supine position. After successful spinal anesthesia, general anesthesia was induced with fentanyl 1.5-2 µg/kg, propofol 2-3 mg/kg, and lidocaine 1.5 mg/kg. Endotracheal intubation was facilitated by cis-atracurium 0.15 mg/kg. Heart rate, systolic, and diastolic blood pressure were recorded at 5, 10, 20, 30, 60, 120, 180 minutes. Anesthesia and muscle relaxation were maintained by isoflurane 1- 1.5 MAC in 50% oxygen/air mixture and cis-atracurium 0.03 mg/kg bolus given every 30 min. respectively.

At the end of surgery, muscle relaxation was reversed by neostigmine 50 µg/kg and atropine 20 µg/kg. Patients were extubated and transferred to postanesthesia care unit (PACU) and were monitored for vital signs (heart rate, non invasive blood pressure, respiratory rate, and O2 saturation) immediately postoperative and at 2, 4, 6, 12, 18, and 24 hours postoperative.

VAS scores were assessed at the same time points. Rescue analgesia represented by patient-controlled analgesia (PCA) with intravenous morphine with an initial bolus of 0.1 mg/kg once pain was expressed by the patient, or if VAS was 3 or more (VAS ≥ 3) followed by 1 mg boluses with a lockout period of 5 min. The time of first request of analgesia and total analgesic consumption in the first 24 hours postoperatively were recorded.

The patient's level of sedation was assessed at the same time points using a modified Observer's Assessment of alertness/sedation (OAAS) scale (where 6 = agitated, and 0 = doesn't respond to deep stimuls).

The attendant anesthesiologist, the patient-care giver, and the data collection personnel were all blinded to patient assignment to a specific group. Postoperative adverse effects such as nausea, vomiting, hypotension, bradycardia, cardiac arrhythmias were recorded and treated.

Hypotension was defined as a 15% decrease in systolic blood pressure from baseline. Bradycardia was defined as a heart rate slower than 50 beats per minute or a decrease in heart rate of 20% or more from baseline; whichever is lowest. Hypoxia was defined as an oxygen saturation of less than 90%. Hypotension was treated with intravenous boluse of ephidrine 0.1 mg/kg and normal saline 5ml/kg; the same doses were repeated as required. Bradycardia was treated with intravenous atropine 0.01 mg/kg.

Being tested
intrathecal drug administration, Dexmedetomidine, ketamine, Bupivacaine
Keywords
dexmedetomidine, ketamine, postoperative pain
Medical subject headings
Agnosia, Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • intrathecal drug administrationProcedure or surgery

    pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.

  • DexmedetomidineDrug

  • ketamineDrug

  • BupivacaineDrug

Study groups in NCT02455609
Study groupRoleWhat they receive
dexmedetomidine (I)Active comparatorintrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
Receives: Procedure: intrathecal drug administration; Drug: Dexmedetomidine; Drug: Bupivacaine
ketamine (II)Active comparatorintrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
Receives: Procedure: intrathecal drug administration; Drug: ketamine; Drug: Bupivacaine
Dexmedetomidine + Ketamine group (III)Active comparatorintrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
Receives: Procedure: intrathecal drug administration; Drug: Dexmedetomidine; Drug: ketamine; Drug: Bupivacaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual Analogue Scale (VAS)

    efficacy of analgesia

    Measured: the first 24 hours postoperative

Secondary outcomes (3)
  1. time to first request of analgesia

    time needed by participating patients in each group to ask for rescue analgesia during the first 24 hours postoperative

    Measured: the first 24 hours postoperative

  2. total analgesic consumption

    total amount of rescue analgesic taken by patients in each group during the first 24 hours postoperative

    Measured: the first 24 hours postoperative

  3. side effects

    incidence of nausea (no.), vomiting (no.), hypotension (mmHg), bradycardia (b/m), hypertension (mmHg), arrhythmia (no.), sedation (by a 0-4 sedation scale) experienced by participating patients in each group

    Measured: the first 24 hours postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 May 2015 (estimated)
  2. Study startMar 2015
  3. Primary completionAug 2015 (estimated)
  4. Study completionSep 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02455609
Sponsor's protocol ID
210
Status last verified
May 2015
First submitted
18 May 2015
Last updated
28 May 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing intrathecal drug administration, Dexmedetomidine and ketamine in people with Therapy and Pain Management, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 May 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Analogue Scale (VAS) (time frame: the first 24 hours postoperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in